ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W, Wang ZJ, Zhang K, Li B, Cai YR, Wen FC, Zhang D, Bai YZ, Zhang XY, Wang SY, Cheng L, Zhong H, Liu L, Wang J, Han BH.
Nie W, et al. Among authors: cheng l.
BMC Med. 2022 May 5;20(1):170. doi: 10.1186/s12916-022-02360-x.
BMC Med. 2022.
PMID: 35509036
Free PMC article.